Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.33 |
| ▸ | DRD1 | P21728 | 4/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19981482 | 0.77 | PNMT (0.33) | TSHRRAB9A | |
| SCHEMBL11987809 | 0.77 | KCNH2 (0.41) | KCNH2DRD2DRD1HTR1AGAA | |
| SCHEMBL12044708 | 0.70 | ALDH1A1 (0.38) | KCNH2DRD2DRD1HTR1ANPC1 | |
| SCHEMBL16024363 | 0.68 | KCNH2 (0.42) | KCNH2DRD2DRD1HTR1A | |
| SCHEMBL18723911 | 0.67 | KCNH2 (0.39) | KCNH2GAANPC1ALDH1A1GLA | |
| SCHEMBL18723592 | 0.67 | KCNH2 (0.39) | KCNH2GAANPC1ALDH1A1GLA | |
| SCHEMBL12045180 | 0.67 | KCNH2 (0.35) | KCNH2DRD2DRD1HTR1AGAA | |
| SCHEMBL18723861 | 0.65 | KCNH2 (0.35) | KCNH2 | |
| SCHEMBL12644058 | 0.65 | TAAR1 (0.43) | KCNH2DRD2HTR1AALDH1A1HPGD | |
| SCHEMBL2040442 | 0.65 | KEAP1 (0.54) | KCNH2DRD2DRD1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, LCK | KCNH2 2252/4885DRD2 4128/4885DRD1 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.